a88a1582-88b8-4e7e-9baf-09279b49a492
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.500
- PROTEIN_SECRETION+0.400
- ALLOGRAFT_REJECTION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- DNA_REPAIR+0.200
- INFLAMMATORY_RESPONSE+0.200
Top 10 suppressed
- ANGIOGENESIS-0.400
- APICAL_SURFACE-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- MYOGENESIS-0.300
- COAGULATION-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- HEDGEHOG_SIGNALING-0.200
- HYPOXIA-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516083 | — | — | 0.824 |
| 2 | TCGA-CQ-5331-01A-02R-1873-07 | — | — | 0.801 |
| 3 | SRR12202424 | — | — | 0.789 |
| 4 | MNG784 | — | — | 0.778 |
| 5 | 88302 | EPN | Supratentorial EPN | 0.770 |
| 6 | SRR1516059 | — | — | 0.762 |
| 7 | MNG833 | — | — | 0.756 |
| 8 | SRR33532827 | — | D | 0.754 |
| 9 | SRR8518291 | — | D | 0.751 |
| 10 | b652254e-228b-40d4-be79-536ad87dad69 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |